Repaglinide (REP), an antidiabetic drug, is recently explored in ameliorating neurodegenerative disorders (Huntington’s and Alzheimer’s disease) by targeting neuronal calcium sensors (DREAM/ATF6 pathway). The repurposing ...

Continual strategies to devise a complete therapeutic cure for neurodegenerative conditions has been a challenge, majorly due to the presence of blood brain barrier. Lack of targeted delivery in order to minimize loss of ...

In metabolic syndrome, dysregulated signalling activity of the insulin receptor pathway in the brain due to persistent insulin resistance (IR) condition in the periphery may lead to brain IR (BIR) development. BIR causes ...

Parkinson’s disease is the second most prevalent neurological disease after Alzheimer’s. Primarily, old age males are more affected than females. The aggregates of oligomeric forms of α-synuclein cause the loss of dopaminergic ...

The signaling pathways upstream of glycogen synthase kinase-3β (GSK-3β) get reduced during ischemic preconditioning (IPC) in hyperlipidemic rat heart. Pioglitazone, an insulin sensitizer, exerts cardioprotection through ...

Multiple biological barriers and discrepancy in releasing the optimal dosage range pose a great challenge in the current therapeutic management for majority of diseases. Nanoparticle drug delivery system (5–250 nm) possesses ...

Trigonelline (TR), 4-hydroxyisoleucine (4-HI), and diosgenin (DG) are the main bioactives of the purified standardized extract of the popular plant Trigonella foenum-graecum L. (TFG), and it has been proven effective for ...

Repaglinide (REP) an insulinotropic agent used in the treatment of type-2 diabetes. It belongs to meglitinides, which act by blocking the ATP sensitive potassium channels and stimulates the insulin release. REP is the first ...

Anomalies in brain insulin signaling have been demonstrated to be involved in the pathology of Alzheimer disease (AD). In this context, the neuroprotective efficacy of an insulin sensitizer, rosiglitazone, has been confirmed ...

For the past several years, dementia, is one of the predominantly observed groups of symptoms in a geriatric population. Alzheimer’s disease (AD) is a progressive memory related neurodegenerative disease, for which the ...